"10.1371_journal.pone.0116718","plos one","2015-02-09T00:00:00Z","Ashutosh Malhotra; Michaela Gündel; Abdul Mateen Rajput; Heinz-Theodor Mevissen; Albert Saiz; Xavier Pastor; Raimundo Lozano-Rubi; Elena H Martinez-Lapsicina; Irati Zubizarreta; Bernd Mueller; Ekaterina Kotelnikova; Luca Toldo; Martin Hofmann-Apitius; Pablo Villoslada","Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, 53754, Sankt Augustin, Germany; Merck KGaA, Darmstadt, Germany; MS Center, Department of Neurology, Hospital Clinic of Barcelona, Barcelona, Spain; Center of Neuroimmunology, Institut dinvestigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Informatics, Hospital Clinic of Barcelona—University of Barcelona, Barcelona, Spain","Conceived and designed the experiments: AM MHA PV LT XP RL. Performed the experiments: AM EML EK TM MG AS AMR BM HTM IZ. Contributed reagents/materials/analysis tools: TM MG BM LT AMR HTM IZ. Wrote the paper: AM MHA EML PV.","Ashutosh Malhotra has no conflicts of interest to disclose. Michaela Gündel has no conflicts of interest to disclose. Abdul Mateen Rajput has been sponsored by Merck KGaA, a chemical and pharmaceutical company. Heinz-Theodor Mevissen has no conflicts of interest to disclose. Albert Saiz received remuneration for consulting and lecturing services from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical and Novartis. Xavier Pastor has no conflicts of interest to disclose. Raimundo Lozano-Rubi has no conflicts of interest to disclose. Elena H. Martínez-Lapiscina has received travel and accommodation expenses for national and international congresses from Novartis, Teva, Sanofi Aventis, Lundbeck and Bayer. Bernd Mueller has no conflicts of interest to disclose. Ekaterina Kotelnikova has no conflicts of interest to disclose. Luca Toldo has been sponsored by Merck KGaA, a chemical and pharmaceutical company. Martin Hofmann-Apitius has no conflicts of interest to disclose. Pablo Villoslada has received: consultancy fees from Roche, Novartis, MedImmune, TFS, Heidelberg Engineering, Digna Biotech, Neurotec Farma; research grants from Novartis and Roche; travel grants from Biogen, Novartis and Merk-Serono; and he is a founder and shareholder of Bionure Farma. The authors confirm that Pablo Villoslada is serving as academic editor for PLOS ONE. Also, the authors confirm that the conflict of interest stated does not alter the authors adherence to PLOS ONE Editorial policies and criteria.","2015","02","Ashutosh Malhotra","AM",14,TRUE,6,10,NA,4,TRUE,FALSE,FALSE,0,NA,FALSE
